OXFORD, England, September 26, 2011 /PRNewswire/ --
PharmaVentures, the experts in deals and alliances, announced today that Corp-METRx, the new definitive analysis on the dealmaking and financial performance of the top 12 pharmaceutical companies, is launched.
The first release of this monthly report on all of the top 12 pharmaceutical companies shows Pfizer has overtaken GlaxoSmithKline and are now placed second only to Roche in the industry's new Deal Activity League Table*. The first monthly edition is available as a free download on our website (http://www.pharmadeals.net/corpmetrx). The ranking information and expert insight from PharmaVentures will be invaluable to analysts, M&A and corporate finance professionals in investment banks, hedge funds, large cap advisory and asset management firms as well as business development and competitive intelligence professionals, chief executives and other senior managers within pharmaceutical and biotechnology companies."
PharmaDeals® Corp-METRx provides key metrics on the relative strengths and weaknesses of the world's top 12 pharmaceutical companies, and is delivered in a concise and instantly accessible online format. This new publication, edited by PharmaVentures' expert, Nigel Borshell, provides an essential look-up for key facts about how major pharmaceutical companies' deal making activities vary, the impact this has on their peer group ranking and how this evolves with time.
Anne Vindenes Allen, PharmaDeals' Executive Director, says, "The industry was in need of a report that would readily analyse how well top companies are performing as deal makers, and PharmaDeals Corp-METRx does just that. Reports on each company are available, along with our expert assessment reviewing the changes of all those 12 companies."
Download the free first edition of PharmaDeals Corp-METRx and read the monthly review article now:
Note to Editors
If you wish to write an article, please contact us for any further information you require.
About PharmaDeals Corp-METRx (http://www.pharmadeals.net/corpmetrx)
- Which of the top 12 is the deal making leader for different therapeutic areas.
- Who is striking the most deals in the short term.
- How do they rank in terms of their long term deal strategies.
- Who are the most acquisitive in the M&A sector
- How are these companies balancing internal and external pipeline filling.
- Abbott Laboratories
- Bayer Healthcare
- Bristol-Myers Squibb
- Eli Lilly
- Johnson & Johnson
PharmaVentures (http://www.pharmaventures.com) is an international healthcare advisory group providing leadership in all aspects of deals and alliances, from strategy formulations to implementation. The company occupies a special position in the global marketplace because of our track record of successful outcomes, resulting from our unique insight into the world of deal making, our internationally recognised analytical and valuation capabilities, our own proprietary deal making database PharmaDeals® (http://www.pharmadeals.net),
containing over 40,000 deal records, and our extensive business relationship network and our outstanding success in M&A transactions. Its subsidiary, PharmaTelevision (http://www.pharmatelevision.com) produces the world's first dedicated online pharmaceutical television channel.
Our Services Cover:
Valuation (for licensing, acquisitions, divestments, fund raising & expert testimonies)
Licensing (In and Out licensing)
M&A (Companies & Assets)
Strategy (commercialisation, deal strategy, due diligence, market entry)
Expert Testimony (Patent Infringement, Deal Disagreements, Taxation, Determining Damages)
Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.
*Source: (PharmaDeals Corp-METRx, Pfizer, August 2011, DOI 10.3833/pdcmx.v2011i2.1540).
PharmaDeals® Is a registered Trade Mark of PharmaVentures Ltd.
For further information, contact:
Anne Vindenes Allen
Executive Director, PharmaDeals
SOURCE PharmaVentures Ltd